Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 7, 2014. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and treasury holdings.
- Shares Purchased: 431,500 Ordinary Shares of 25 pence each.
- Purchase Date: May 7, 2014.
- Price Range: Highest price paid was 1,628.50 pence per share; lowest price paid was 1,615.00 pence per share.
- Treasury Holdings (Settled): 489,174,669 shares (9.14% of total issued share capital).
- Treasury Holdings (Including Unsettled): 490,005,169 shares (10.08% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,861,094,607 shares.
Material Changes
The filing reports an incremental increase in the company's treasury share holdings following the purchase of 431,500 shares. No other material changes to financial position or operations are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under the Financial Conduct Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the company's latest annual report to confirm the 9.14% ownership stake.
- Confirm the settlement status of the 431,500 shares purchased on May 7, 2014, to reconcile the difference between settled and unsettled treasury holdings.
- Review the company's ongoing share buyback program limits to determine remaining authorization for future repurchases.